Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.54 |
| ▸ | SENP2 | Q9HC62 | 11/20 | 0.42 |
| ▸ | SENP1 | Q9P0U3 | 11/20 | 0.42 |
| ▸ | SENP5 | Q96HI0 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7942773 | 0.88 | BACE1 (0.41) | BACE1 | |
| SCHEMBL7940504 | 0.86 | PTGDR2 (0.40) | BACE1 | |
| SCHEMBL7944478 | 0.82 | BACE1 (0.55) | BACE1 | |
| SCHEMBL7941730 | 0.80 | BACE1 (0.59) | BACE1 | |
| SCHEMBL7942148 | 0.78 | BACE1 (0.61) | BACE1SENP2SENP1SENP5MAPT | |
| SCHEMBL7933183 | 0.78 | BACE1 (0.71) | BACE1 | |
| SCHEMBL7940400 | 0.77 | BACE1 (0.60) | BACE1 | |
| SCHEMBL7942027 | 0.76 | BACE1 (0.58) | BACE1SENP2SENP1SENP5 | |
| SCHEMBL7942031 | 0.75 | BACE1 (0.65) | BACE1 | |
| SCHEMBL7942157 | 0.75 | BACE1 (0.60) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885SENP2 231/4885SENP1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.